Review
Oncology
Francesco Guida, Shayan Dioun, Anna Fagotti, Alexander Melamed, Adriano Grossi, Giovanni Scambia, Jason D. Wright, Ana I. Tergas
Summary: This study evaluates the clinical utility of tertiary cytoreductive surgery in recurrent ovarian cancer through a systematic review and meta-analysis. The results show that optimal tertiary cytoreductive surgery is associated with improved disease specific survival and overall survival compared to suboptimal tertiary cytoreductive surgery.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Nicole E. James, Morgan Woodman, Jennifer R. Ribeiro
Summary: EOC patients have low response rates to immunotherapies, but evidence suggests ovarian tumors are immunogenic and immune-related genomic profiles can serve as prognostic markers. Specific research areas that need to be addressed include developing immune-based prognostic signatures and driving advancements in this field.
Review
Medicine, General & Internal
Jiaduo Li, Yaling Liu, Xiaohe Zhang, Xuguang Zheng, Guoyan Qi
Summary: This meta-analysis examined prognostic factors in patients with surgically resected thymic epithelial tumors (TETs) and found that advanced age, incomplete resection, WHO classification B2/B3, and higher Masaoka stage are risk factors for poor prognosis.
Review
Oncology
Qingyi Wang, Xiaoling Feng, Xiaofang Liu, Siyu Zhu
Summary: According to the meta-analysis, higher pretreatment serum CA-125 levels are associated with poor prognosis in epithelial ovarian cancer (EOC) patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Aya El Helali, Charlene H. L. Wong, Horace C. W. Choi, Wendy W. L. Chan, Naomi Dickson, Steven W. K. Siu, Karen K. Chan, Hextan Y. S. Ngan, Roger K. C. Ngan, Richard D. Kennedy
Summary: This study conducted a systematic review and network meta-analysis to evaluate the efficacy of anti-angiogenic agents in epithelial ovarian cancer. The results showed that the concurrent use of trebananib with chemotherapy may be the best option for recurrent EOC. Additionally, bevacizumab plus chemotherapy followed by maintenance bevacizumab and pazopanib combined with chemotherapy were identified as the interventions with the highest probability of improving overall survival in high-risk chemotherapy-naive and platinum-resistant EOC, respectively. However, anti-angiogenic agents may not have a significant clinical role in non-high-risk chemotherapy-naive and platinum-sensitive EOC.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Violante Di Donato, Andrea Giannini, Ottavia D'Oria, Michele Carlo Schiavi, Anna Di Pinto, Margherita Fischetti, Francesca Lecce, Giorgia Perniola, Francesco Battaglia, Pasquale Berloco, Ludovico Muzii, Pierluigi Benedetti Panici
Summary: The study aimed to evaluate the feasibility and safety of cytoreduction in patients with advanced ovarian cancer and hepato-biliary metastasis. Results showed that 20.9% of patients had liver, biliary tract, or porta hepatis metastasis, with 71.6% achieving complete cytoreduction. Severe complications related to hepatobiliary surgery were reported in 2.9% of patients, but complete cytoreduction was associated with survival benefits.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Se Ik Kim, Ji Hyun Kim, Sanghee Lee, Hyunsoon Cho, Willemien J. van Driel, Gabe S. Sonke, Robert E. Bristow, Sang-Yoon Park, Christina Fotopoulou, Myong Cheol Lim
Summary: This study systematically evaluated the value of hyperthermic intraperitoneal chemotherapy (HIPEC) in cytoreductive surgery (CRS) for epithelial ovarian cancer (EOC). The results showed that HIPEC improved progression-free survival (PFS) and overall survival (OS) in the recent chemotherapy exposure group, but had no significant effect in the non-recent chemotherapy exposure group.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Oncology
Malika Kengsakul, Gatske M. Nieuwenhuyzen-de Boer, Anna H. J. Bijleveld, Suwasin Udomkarnjananun, Stephen J. Kerr, Christa D. Niehot, Heleen J. van Beekhuizen
Summary: Enlarged cardiophrenic lymph node (CPLN) in preoperative imaging is highly associated with metastatic involvement and lower survival rate in patients with advanced-stage epithelial ovarian cancer (AEOC). Further randomized controlled trials should be conducted to definitively demonstrate whether CPLN resection at the time of cytoreductive surgery is beneficial.
Review
Oncology
Giuseppe Caruso, Innocenza Palaia, Giorgio Bogani, Federica Tomao, Giorgia Perniola, Pierluigi Benedetti Panici, Ludovico Muzii, Violante Di Donato
Summary: For advanced epithelial ovarian cancer patients, systematic lymph node dissection (SyLND) after neoadjuvant chemotherapy (NACT) did not significantly improve progression-free survival (PFS) and overall survival (OS), and resulted in a higher risk of severe postoperative complications.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)
Review
Obstetrics & Gynecology
AlBatool M. AlMahdy, Gena M. Elassall, Ahmed Y. Abdelbadee, Ahmed Y. Abd-Elkariem, Fatma Atef, Islam A. Ahmed, Esraa G. Sayed, Mohamed Ashraf Salah, Ahmed K. Ali, Esraa Y. Ragab, Hossam Aldein S. Abd Elazeem, Mahmoud M. Saad, Sherif A. Shazly
Summary: The study found that systematic lymphadenectomy was associated with improved overall survival in women with ovarian cancer, especially those who underwent adjuvant chemotherapy. The survival benefit of systematic lymphadenectomy varied among patients with different stages, but did not improve survival in women who received neoadjuvant chemotherapy.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
(2021)
Review
Oncology
Juan Chen, Xiaoyan Shi, Lan Xiao, Zelian Li, Zhimin Li, Lei Sun
Summary: This study aimed to investigate the relationship between subtypes of high-grade serous ovarian carcinoma (HGSOC) and survival outcomes. The results showed no statistically significant differences in overall survival (OS) between the mesenchymal subtype and other subtypes of HGSOC, but a significant difference was observed in progression-free survival (PFS). Further evidence is needed to confirm the conclusion that the mesenchymal subtype may have a poorer PFS.
Review
Oncology
Haiyan Zhang, Jing Li, Qi Zhou
Summary: The high expression of IDO1 is associated with shorter overall survival and disease-free survival in patients with solid tumors, making it a potential prognostic marker in various cancer types.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Patriciu Andrei Achimas-Cadariu, Diana Loreta Paun, Andrei Pasca
Summary: This systematic review and meta-analysis investigated the safety and effect of Hormone Replacement Therapy (HRT) on overall survival and progression-free survival in ovarian cancer treatments. The results showed a slight benefit in terms of survival and recurrence rates in favor of the HRT groups. However, subgroup analyses revealed no statistically significant results in terms of recurrence, but HRT remains advantageous in improving the quality of life for these patients.
Review
Multidisciplinary Sciences
Sung Ryul Shim, Sun Il Kim, Se Joong Kim, Dae Sung Cho
Summary: This study found that the prognostic nutritional index (PNI) has good diagnostic accuracy as a prognostic factor for renal cell carcinoma (RCC), especially in case of metastatic RCC.
Review
Oncology
Saverio Caini, Marco Del Riccio, Virginia Vettori, Giulio Francolini, Oriana D'Ecclesiis, Tommaso Cai, Aurora Gaeta, Guglielmo Bonaccorsi, Ines Zanna, Domenico Palli, Sara Gandini
Summary: Cigarette smoking increases the risk of bladder cancer, but there is insufficient evidence on whether quitting smoking at or around diagnosis is beneficial for the prognosis of bladder cancer patients.